Organon and Samsung Bioepis announced that Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab), is now available in the US. Hadlima® is available at a list price of $1,038, an 85% discount in comparison to the list price of Humira®.
On 1 July 2023, the following biosimilar entities are licensed to launch: Alvotech, Celltrion, Boehringer Ingelheim, Coherus before Fresenius Kabi in July (on an unspecified date), Mylan/Viatris on 31 July 2023, Sandoz on 30 September 2023, Momenta and Pfizer on 20 November 2023.
Print Page Mail Article